J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II …
Post
-
-
GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
GSK’s $2bn bid on Bellus Health has taken a knock, as the British pharma giant is terminating the late-stage refractory …
-
Trellis Bioscience secures Series C financing for TRL1068 trial
Trellis Bioscience has closed a $9m Series C funding round to support the completion of its ongoing Phase II clinical …
-
Takeda unveils secondary endpoint data from Phase III PsO pill trials
Takeda has released data for its plaque psoriasis (PsO) pill in key secondary endpoints in high-impact areas, supporting a route …
-
First patients dosed in Grifols Phase III immunoglobulin trials
Grifols has dosed the first patients in two separate Phase III trials designed to support the US label expansion of …
-
AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact
Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines the potential …
-
MASH therapy enters a more competitive era
For much of the last two years, there has only been one real way to treat metabolic dysfunction-associated steatohepatitis (MASH). …
-
MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166
MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral …
-
Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other …
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's …
-
Veradermics stock jumps again on female hair loss drug win
Veradermics has seen another jump in its stock price as its hair loss drug showed benefit in women with androgenetic alopecia …
-
Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development
As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate …
-
Loneliness interventions do not have strong sustained effects on memory function
Loneliness, defined as a subjective experience of a discrepancy between the preferred interpersonal relationship an individual has and their actual …
-
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement …
-
FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072
Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
